Research
Hormonal
At maximum approved doses, tirzepatide (15 mg) produces significantly greater weight loss and glycemic improvement than semaglutide (2.4 mg).
If you are treating obesity with GLP-1/GIP agonists at their maximum FDA-approved doses, Tirzepatide (15 mg) will likely produce more weight loss and better blood sugar control than Semaglutide (2.4 mg). However, cost and availability may make Semaglutide a more practical first choice for some patients.
StrongSupportsVERY_HIGH confidence
Tirzepatide demonstrated superiority over semaglutide in percentage weight reduction (mean difference [MD] 6.10%; 95% CI: 3.64, 8.57), absolute weight loss (MD 4.55 kg; 95% CI: 1.28, 7.83), BMI reduction (MD 1.71 kg/m2; 95% CI: 0.08, 3.34), and waist circumference reduction (MD 2.89 cm; 95% CI: 1.25, 4.53).
Why this rating
Network meta-analysis of 28 RCTs with 34,367 participants and high certainty of evidence (GRADE).
Source
Who Wins the Battle Against Obesity? A Network Meta‐Analysis Comparing Tirzepatide and Semaglutide
Júlia Cremonini Bernardi et al. · Journal of Diabetes · 2026
Meta-analysis · 28 studiesCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →